Results 281 to 290 of about 184,737 (335)

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

open access: yesMolecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala   +15 more
wiley   +1 more source

Oncologists' perspective on advance directives, a French national prospective cross-sectional survey - the ADORE study. [PDF]

open access: yesBMC Med Ethics
Cambriel A   +8 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy